Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Eagan

Showing results (41-50 of 111) with videos related to

Pageof 12
Sort By:
Cancer Investigation|January 1, 1988
Treatment of "limited" stage III non-small cell carcinoma of the lungS Frytak, R T Eagan, K Sawamura, et al.
Journal of the National Cancer Institute|January 1, 1978
Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communicationR T Eagan, J N Ingle, J Rubin, et al.
Cancer Treatment Reports|July 1, 1976
ICRF-159 versus polychemotherapy in non-small cell lung cancerR T Eagan, D T Carr, D T Coles, et al.
Cancer Treatment Reports|October 1, 1978
Phase II evaluation of maytansine in patients with metastatic lung cancerR T Eagan, E T Creagan, J N Ingle, et al.
Cancer Treatment Reports|July 1, 1976
VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancerR T Eagan, D T Carr, S Frytak, et al.
Cancer Treatment Reports|July 1, 1984
Phase I study of diaziquoneS Frytak, R T Eagan, M M Ames, et al.
Cancer Treatment Reports|March 1, 1986
Phase II trial of diaziquone in malignant mesotheliomaR T Eagan, S Frytak, R L Richardson, et al.
American Journal of Clinical Oncology|February 1, 1987
Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trialR T Eagan, T M Therneau, J Rubin, et al.
Cancer Treatment Reports|October 1, 1987
Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancerR T Eagan, C Ruud, R E Lee, et al.
American Journal of Clinical Oncology|February 1, 1986
Phase II study of the three-drug combination of mitomycin C, CCNU, and methotrexate (MCM) in advanced non-small cell lung cancerR T Eagan, S Frytak, R L Richardson, et al.
Pageof 12

Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
Cancer Investigation|January 1, 1988
Treatment of "limited" stage III non-small cell carcinoma of the lungS Frytak, R T Eagan, K Sawamura, et al.
Journal of the National Cancer Institute|January 1, 1978
Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communicationR T Eagan, J N Ingle, J Rubin, et al.
Cancer Treatment Reports|July 1, 1976
ICRF-159 versus polychemotherapy in non-small cell lung cancerR T Eagan, D T Carr, D T Coles, et al.
Cancer Treatment Reports|October 1, 1978
Phase II evaluation of maytansine in patients with metastatic lung cancerR T Eagan, E T Creagan, J N Ingle, et al.
Cancer Treatment Reports|July 1, 1976
VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancerR T Eagan, D T Carr, S Frytak, et al.
Cancer Treatment Reports|July 1, 1984
Phase I study of diaziquoneS Frytak, R T Eagan, M M Ames, et al.
Cancer Treatment Reports|March 1, 1986
Phase II trial of diaziquone in malignant mesotheliomaR T Eagan, S Frytak, R L Richardson, et al.
American Journal of Clinical Oncology|February 1, 1987
Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trialR T Eagan, T M Therneau, J Rubin, et al.
Cancer Treatment Reports|October 1, 1987
Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancerR T Eagan, C Ruud, R E Lee, et al.
American Journal of Clinical Oncology|February 1, 1986
Phase II study of the three-drug combination of mitomycin C, CCNU, and methotrexate (MCM) in advanced non-small cell lung cancerR T Eagan, S Frytak, R L Richardson, et al.
Pageof 12